Terry Roode, DO
Family Medicine · New Bremen, OHNPI 1093749913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 26.6% of the total. Reporting peaked in 2023 at $378 and has fallen 68.4% since, to $119 in 2025.
Across 61 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$260
- Novo Nordisk$152
- Lilly USA, LLC$148
- Abbott$106
- GSK$98
- Amgen$49
- plus $166 from 5 others
What the payments were for
- Food & beverage$979100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $260 |
| Novo Nordisk | 11 | $152 |
| Lilly USA, LLC | 10 | $148 |
| Abbott | 5 | $106 |
| GSK | 5 | $98 |
| Amgen | 3 | $49 |
| Pfizer | 3 | $49 |
| Novartis | 3 | $47 |
| AstraZeneca | 3 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Merck | 1 | $13 |
How this compares
$979 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $116,245 |
| EliquisApixaban | 89 | $97,204 |
| MounjaroTirzepatide | 50 | $53,871 |
| FarxigaDapagliflozin Propanediol | 35 | $42,048 |
| XareltoRivaroxaban | 31 | $33,782 |
| JanuviaSitagliptin Phosphate | 35 | $32,121 |
| TrulicityDulaglutide | 26 | $26,074 |
| Bydureon BciseExenatide Microspheres | 16 | $18,177 |
| Repatha SureclickEvolocumab | 19 | $16,951 |
| JardianceEmpagliflozin | 21 | $16,736 |
| EntrestoSacubitril/Valsartan | 11 | $14,129 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $12,488 |
| MyrbetriqMirabegron | 18 | $10,294 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $10,156 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $152 | $116,245109 claims |
| PfizerEliquis | $49 | $97,20489 claims |
| Lilly USA, LLCMounjaro, Trulicity | $148 | $79,94576 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $40 | $52,07859 claims |
| MerckJanuvia | $13 | $32,12135 claims |
| NovartisEntresto | $47 | $14,12911 claims |
| GSKTrelegy Ellipta | $98 | $8,27613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in New Bremen
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.